Jinghua Hao1, Rohan R Varshney, Dong-An Wang. 1. Nanyang Technological University, School of Chemical and Biomedical Engineering, Division of Bioengineering, 70 Nanyang Drive, N1.3-B2-13, Singapore 637457, Republic of Singapore.
Abstract
BACKGROUND: Engineered organogenesis is one of the most challenging areas on the cutting edge of regenerative medicine. Growth factors can affect cell proliferation, migration and differentiation profoundly, and thus play a critical role in tissue regeneration. TGF-betas produce a wide range of effects in different cells and tissues. TGF-beta3 is relatively recently discovered and studied. OBJECTIVE: To provide a broader understanding of the current state of TGF-beta3 in engineered osteogenesis, chondrogenesis, palate development, scar-free wound healing, odontogenesis and neurogenesis. METHODS: This review summarizes studies that explore or apply TGF-beta3 for organogenesis with engineering methodology and a regenerative medical perspective. RESULTS/ CONCLUSION: TGF-beta3 has proven to be a competent growth factor in engineered organogenesis in vitro. In recent years, using TGF-beta3, more and more in vivo studies have yielded significant therapeutic achievements in animal models, which bear much promise for future medical application.
BACKGROUND: Engineered organogenesis is one of the most challenging areas on the cutting edge of regenerative medicine. Growth factors can affect cell proliferation, migration and differentiation profoundly, and thus play a critical role in tissue regeneration. TGF-betas produce a wide range of effects in different cells and tissues. TGF-beta3 is relatively recently discovered and studied. OBJECTIVE: To provide a broader understanding of the current state of TGF-beta3 in engineered osteogenesis, chondrogenesis, palate development, scar-free wound healing, odontogenesis and neurogenesis. METHODS: This review summarizes studies that explore or apply TGF-beta3 for organogenesis with engineering methodology and a regenerative medical perspective. RESULTS/ CONCLUSION:TGF-beta3 has proven to be a competent growth factor in engineered organogenesis in vitro. In recent years, using TGF-beta3, more and more in vivo studies have yielded significant therapeutic achievements in animal models, which bear much promise for future medical application.
Authors: Bradford E Hall; Umesh D Wankhade; Joanne E Konkel; Karthik Cherukuri; Chandrasekharam N Nagineni; Kathleen C Flanders; Praveen R Arany; Wanjun Chen; Sushil G Rane; Ashok B Kulkarni Journal: J Biol Chem Date: 2013-09-20 Impact factor: 5.157
Authors: Matthew J Finley; Katherine A Clark; Ivan S Alferiev; Robert J Levy; Stanley J Stachelek Journal: Biomaterials Date: 2013-08-13 Impact factor: 12.479